Clinical Trial Update: Phase I Safety Study of a Recombinant MVA HIV Multiantigen Vaccine in HIV-infected Subjects [Phase 1]

View source ↗

Summary

Phase I safety study of recombinant MVA HIV multiantigen vaccine in HIV-infected subjects has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• MVA HIV multiantigen vaccine (recombinant Modified Vaccinia Ankara HIV multiantigen vaccine)

Snippet

Sponsor: Bavarian Nordic | Conditions: HIV Infections | Phase 1 | Status: COMPLETED